Groundbreaking Multi-Center Clinical Trial Confirms Low-Dose Aspirin Therapy Reduces Rate of Pre-Term Preeclampsia

LJUBLJANA, Slovenia–(BUSINESS WIRE)–PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the publication of the Fetal Medicine Foundation’s (FMF’s) Project “ASPRE” study results in The New England Journal of Medicine. These compelling findings revealed that administering low-dose aspirin (150 mg) led to a 62% reduction in the rate of pre-term preeclampsia (resulting in delivery before 37 weeks). In addition, the study found an 82% reduction in the
Source: BusinessWire-Primary

Groundbreaking Multi-Center Clinical Trial Confirms Low-Dose Aspirin Therapy Reduces Rate of Pre-Term Preeclampsia